REGENXBIO (RGNX) Competitors $9.63 -1.51 (-13.55%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RGNX vs. SGMO, ALEC, QURE, CCCC, BDTX, EVO, AKRO, CNTA, HRMY, and RXRXShould you be buying REGENXBIO stock or one of its competitors? The main competitors of REGENXBIO include Sangamo Therapeutics (SGMO), Alector (ALEC), uniQure (QURE), C4 Therapeutics (CCCC), Black Diamond Therapeutics (BDTX), Evotec (EVO), Akero Therapeutics (AKRO), Centessa Pharmaceuticals (CNTA), Harmony Biosciences (HRMY), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "medical" sector. REGENXBIO vs. Sangamo Therapeutics Alector uniQure C4 Therapeutics Black Diamond Therapeutics Evotec Akero Therapeutics Centessa Pharmaceuticals Harmony Biosciences Recursion Pharmaceuticals REGENXBIO (NASDAQ:RGNX) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, community ranking, risk, media sentiment and profitability. Which has preferable valuation and earnings, RGNX or SGMO? Sangamo Therapeutics has higher revenue and earnings than REGENXBIO. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioREGENXBIO$90.24M5.29-$263.49M-$5.03-1.91Sangamo Therapeutics$176.23M2.43-$257.83M-$0.75-2.73 Does the MarketBeat Community believe in RGNX or SGMO? Sangamo Therapeutics received 13 more outperform votes than REGENXBIO when rated by MarketBeat users. However, 65.81% of users gave REGENXBIO an outperform vote while only 62.55% of users gave Sangamo Therapeutics an outperform vote. CompanyUnderperformOutperformREGENXBIOOutperform Votes43365.81% Underperform Votes22534.19% Sangamo TherapeuticsOutperform Votes44662.55% Underperform Votes26737.45% Which has more volatility and risk, RGNX or SGMO? REGENXBIO has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Is RGNX or SGMO more profitable? Sangamo Therapeutics has a net margin of -257.87% compared to REGENXBIO's net margin of -283.19%. REGENXBIO's return on equity of -70.65% beat Sangamo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets REGENXBIO-283.19% -70.65% -41.68% Sangamo Therapeutics -257.87%-264.16%-107.24% Do insiders & institutionals have more ownership in RGNX or SGMO? 88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 13.1% of REGENXBIO shares are held by insiders. Comparatively, 2.8% of Sangamo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media prefer RGNX or SGMO? In the previous week, Sangamo Therapeutics had 1 more articles in the media than REGENXBIO. MarketBeat recorded 20 mentions for Sangamo Therapeutics and 19 mentions for REGENXBIO. Sangamo Therapeutics' average media sentiment score of 0.66 beat REGENXBIO's score of 0.39 indicating that Sangamo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Sangamo Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate RGNX or SGMO? REGENXBIO currently has a consensus target price of $35.64, indicating a potential upside of 270.06%. Sangamo Therapeutics has a consensus target price of $7.00, indicating a potential upside of 241.46%. Given REGENXBIO's stronger consensus rating and higher possible upside, analysts clearly believe REGENXBIO is more favorable than Sangamo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score REGENXBIO 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92Sangamo Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 SummaryREGENXBIO beats Sangamo Therapeutics on 11 of the 18 factors compared between the two stocks. Ad Behind the MarketsUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?Click Here to learn how to get in now >>> Get REGENXBIO News Delivered to You Automatically Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGNX vs. The Competition Export to ExcelMetricREGENXBIOBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$477.12M$2.94B$5.12B$8.72BDividend YieldN/A1.81%5.18%4.07%P/E Ratio-1.9120.4872.8114.16Price / Sales5.29224.491,250.2081.71Price / CashN/A176.6640.7036.03Price / Book1.584.056.455.94Net Income-$263.49M-$42.42M$119.73M$225.73M7 Day Performance-13.71%-10.63%-5.13%-1.34%1 Month Performance-9.15%-5.81%-2.71%1.15%1 Year Performance-50.59%24.19%31.08%24.02% REGENXBIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGNXREGENXBIO4.377 of 5 stars$9.63-13.6%$35.64+270.1%-48.9%$477.12M$90.24M-1.91344Analyst ForecastNews CoverageGap UpHigh Trading VolumeSGMOSangamo Therapeutics2.2761 of 5 stars$2.06-4.2%N/A+484.5%$429.76M$176.23M-2.75480Earnings ReportAnalyst ForecastAnalyst RevisionALECAlector4.3865 of 5 stars$4.35-11.4%N/A+3.2%$426.01M$61.51M-2.56270News CoverageQUREuniQure3.4762 of 5 stars$6.56-2.8%N/A-3.5%$319.73M$15.84M-1.32500Short Interest ↓CCCCC4 Therapeutics2.1453 of 5 stars$4.47-5.3%N/A+136.8%$315.53M$33.67M-2.63150Short Interest ↓BDTXBlack Diamond Therapeutics3.0613 of 5 stars$2.73-4.2%N/A+21.3%$154.46MN/A-2.0590Short Interest ↓Positive NewsEVOEvotec1.027 of 5 stars$5.59+9.6%N/A-44.7%$1.98B$845.74M0.005,061Short Interest ↓News CoverageGap UpHigh Trading VolumeAKROAkero Therapeutics4.0236 of 5 stars$28.01-5.9%N/A+94.5%$1.96BN/A-7.4730Earnings ReportShort Interest ↓Analyst RevisionNews CoverageCNTACentessa Pharmaceuticals3.8575 of 5 stars$17.19-1.8%N/A+129.2%$1.95B$6.85M-11.2472Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageHRMYHarmony Biosciences4.8494 of 5 stars$32.93-0.2%N/A+28.5%$1.88B$582.02M15.61200Short Interest ↓RXRXRecursion Pharmaceuticals2.1201 of 5 stars$6.38-7.7%N/A-7.4%$1.79B$44.58M-4.17400Insider Selling Related Companies and Tools Related Companies SGMO Alternatives ALEC Alternatives QURE Alternatives CCCC Alternatives BDTX Alternatives EVO Alternatives AKRO Alternatives CNTA Alternatives HRMY Alternatives RXRX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RGNX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding REGENXBIO Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share REGENXBIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
